Revance Therapeutics, Inc.
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II cli… Read more
Market Cap & Net Worth: Revance Therapeutics, Inc. (RVNC)
Revance Therapeutics, Inc. (NASDAQ:RVNC) has a market capitalization of $381.02 Million ($381.02 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12342 globally and #5321 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Revance Therapeutics, Inc.'s stock price $3.65 by its total outstanding shares 104390000 (104.39 Million).
Revance Therapeutics, Inc. Market Cap History: 2015 to 2025
Revance Therapeutics, Inc.'s market capitalization history from 2015 to 2025. Data shows change from $3.57 Billion to $381.02 Million (-19.74% CAGR).
Revance Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Revance Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.92x
Revance Therapeutics, Inc.'s market cap is 3.92 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.57 Billion | $300.00K | -$73.48 Million | 11886.54x | N/A |
| 2016 | $2.16 Billion | $300.00K | -$89.27 Million | 7202.91x | N/A |
| 2017 | $3.73 Billion | $262.00K | -$120.59 Million | 14244.06x | N/A |
| 2018 | $2.10 Billion | $3.73 Million | -$142.57 Million | 563.52x | N/A |
| 2019 | $1.69 Billion | $413.00K | -$156.22 Million | 4102.30x | N/A |
| 2020 | $2.96 Billion | $15.32 Million | -$282.09 Million | 193.04x | N/A |
| 2021 | $1.70 Billion | $77.80 Million | -$286.82 Million | 21.90x | N/A |
| 2022 | $1.93 Billion | $132.56 Million | -$356.42 Million | 14.54x | N/A |
| 2023 | $917.59 Million | $234.04 Million | -$323.99 Million | 3.92x | N/A |
Competitor Companies of RVNC by Market Capitalization
Companies near Revance Therapeutics, Inc. in the global market cap rankings as of March 19, 2026.
Key companies related to Revance Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Revance Therapeutics, Inc. Historical Marketcap From 2015 to 2025
Between 2015 and today, Revance Therapeutics, Inc.'s market cap moved from $3.57 Billion to $ 381.02 Million, with a yearly change of -19.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $381.02 Million | +20.07% |
| 2024 | $317.35 Million | -65.42% |
| 2023 | $917.59 Million | -52.38% |
| 2022 | $1.93 Billion | +13.11% |
| 2021 | $1.70 Billion | -42.41% |
| 2020 | $2.96 Billion | +74.61% |
| 2019 | $1.69 Billion | -19.37% |
| 2018 | $2.10 Billion | -43.69% |
| 2017 | $3.73 Billion | +72.71% |
| 2016 | $2.16 Billion | -39.40% |
| 2015 | $3.57 Billion | -- |
End of Day Market Cap According to Different Sources
On Feb 5th, 2026 the market cap of Revance Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $381.02 Million USD |
| MoneyControl | $381.02 Million USD |
| MarketWatch | $381.02 Million USD |
| marketcap.company | $381.02 Million USD |
| Reuters | $381.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.